Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: Challenges for the future

International Psychogeriatrics

Volumn 19, Issue 3, 2007, Pages 539-558

  Faison, Warachal E ^a   Schultz, Susan K ^b   Aerssens, Jeroen ^c   Alvidrez, Jennifer ^d   Anand, Ravi ^e   Farrer, Lindsay A ^f   Jarvik, Lissy ^g,h   Manly, Jennifer ⁱ   McRae, Thomas ^j   Murphy Jr , Greer M ^k   Olin, Jason T ^l   Regier, Darrel ^m   Sano, Mary ^h   Mintzer, Jacobo E ^a,n  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Anand Pharma Consulting   (Switzerland)

^f BOSTON UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ NewYork Presbyterian Hospital   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l FOREST RESEARCH INSTITUTE   (United States)

^m AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

ⁿ RALPH H JOHNSON VA MEDICAL CENTER   (United States)

more..

Author keywords

Alzheimer's disease; Dementia; Genetics; Minority issues and cross cultural psychiatry; Social and political issues

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; SABELUZOLE;

AFRICAN AMERICAN; ALZHEIMER DISEASE; ASIAN; CAREGIVER; CAUCASIAN; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; ETHNICITY; GENETIC VARIABILITY; GENETICS; HISPANIC; HUMAN; PATHOGENESIS; RANDOMIZATION; SOCIOECONOMICS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; CROSS-CULTURAL COMPARISON; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GALANTAMINE; HUMANS; INDANS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; THIAZOLES;

EID: 34248168837     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S104161020700511X     Document Type: Conference Paper

References (94)

1. Adams, J., Silverman, M., Musa, D. and Peele, P. (1997). Recruiting older adults for clinical trials. Controlled Clinical Trials, 18, 4-26.
2. Alzheimer's Association (2007). Alzheimer's Disease Facts and Figures 2007. Chicago, IL: Alzheimer's Association.
3. Alzheimer's Foundation of America (2007). ICAN2: Investigating Caregivers' Attitudes and Needs. New York: Alzheimer's Foundation of America (www.alzfdn.org.accessed 26 March 2007).
4. Areán, P. A., Alvidrez, J., Nery, R., Estes, C. and Linkins, C. (2003). Recruitment and retention of older minorities in mental health services research. The Gerontologist, 43, 36-44.
5. Ashery, R. S. and McAuliffe, W. E. (1992). Implementation issues and techniques in randomized clinical trials of outpatient psychosocial treatments for drug abusers: recruitment of subjects. The American Journal of Drug and Alcohol Abuse, 18, 305-329.
6. Ayalon, L. and Areán, P. A. (2004). Knowledge of Alzheimer's disease in four ethnic groups of older adults. International Journal of Geriatric Psychiatry, 19, 51-57.
7. Barnes, L. et al. (2005). Racial differences in the progression of cognitive decline in Alzheimer disease. The American Journal of Geriatric Psychiatry, 13, 959-967.
8. Bell, K. L., Sano, M. C., Jin, S., Thomas, R. G. and Thal, L. J. (1999). Ethnic differences in clinical measures among participants in Alzheimer's disease clinical trials. Neurology, 52, A396.
9. Bonner, G. J. and Miles, T. P. (1997). Participation of African Americans in clinical research. Neuroepidemiology, 16, 281-284.
10. Braveman, P., Cubbin, C., Marchi, K., Egerter, S. and Chavez, G. (2001). Measuring socioeconomic status/position in studies of racial/ethnic disparities: maternal and infant health. Public Health Reports, 116, 449-463.
11. Brawley, O. W. and Tejeda, H. (1995). Minority inclusion in clinical trials issues and potential strategies. Journal National Cancer Institute. Monographs, 17, 55-57.
12. Brodaty, H. and Green, A. (2002). Defining the role of the caregiver in Alzheimer's disease treatment. Drugs and Aging, 19, 891-898.
13. Carew, B. D., Ahn, S. A., Boischot, H. D., Dierenfeldt, B. J., Dolan, N. A. and Edens, T. R. (1992). Recruitment strategies in the studies of left ventricular dysfunction (SOLVD): strategies for screening and enrollment in two current but separate clinical trials. The SOLVD Investigators. Controlled Clinical Trials, 13, 325-338.
14. Collins, M. (1997). Increasing prostate cancer awareness in African-American men. Oncology Nursing Forum, 24, 91-95.
15. Connell, C. M. and Gibson, G. D. (1997). Racial, ethnic and cultural differences in dementia caregiving: review and analysis. The Gerontologist, 37, 355-364.
16. Crawford, E. D., Leewansangtong, S., Goktas, S., Holthaus, K. and Baier, M. (1999). Efficiency of prostate-specific antigens and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. The Prostate. 38, 296-302.
17. el-Sadr, W. and Capps, L. (1992). The challenge of minority recruitment in clinical trials for AIDS. JAMA, 257, 954-957.
18. Engelking, C. (1991). Facilitating clinical trials: the expanding role of the nurse. Cancer, 67, 1793-1797.
19. Faison, W. et al. (2002). Minority participation in Alzheimer's drug trials. Poster presentation at the American Association for Geriatric Psychiatry 15th Annual Meeting, 24-27 February, 2002.
20. Faison, W., Corwin, S., Sano, M. and Mintzer, J. (2004). Decision-making of African Americans to participate in Alzheimer's disease clinical trials. Poster presented at the American College of Neuropsychopharmacology Meeting.
21. Faison, W. and Mintzer, J. (2005a). Participation in Alzheimer's disease clinical trials: a focus on African American Caregivers. Poster presented at the American College of Neuropsychopharmacology Meeting.
22. Faison, W. E. and Mintzer, J. E. (2005b). The growing, ethnically diverse aging population: is our field advancing with it? The American Journal of Geriatric Psychiatry, 13, 541-544.
23. Farrer, W. B. (1991). Clinical trials: access and reimbursement. Cancer, 67 (Suppl. 6), 1779S-1782S.
24. Ferketich, S., Phillips, L. and Verran, J. (1993). Focus on psychometrics: development and administration of a survey instrument for cross-cultural research. Research in Nursing and Health, 16, 227-230.
25. Fillenbaum, G. C. et al. (1998). The prevalence and 3-year incidence of dementia in older Black and White community residents. Journal of Clinical Epidemiology, 51, 587-595.
26. Ford, M. E., Havstad, S. and Stallings, F. L. (1998). Recruiting black men to a clinical trial to evaluate prostate cancer screening - Detroit, Michigan. Morbidity and Mortality Weekly Report, 47, 694-696.
27. Ford, M. E., Havstad, S. L. and Kart, C. S. (2001). Assessing the reliability of the EORTC QLQ-C30 in a sample of older African American and Caucasian adults. Quality of Life Research, 10, 533-541.
28. Ford, M. E. et al. (2002). Categorizing race and ethnicity in the HMO Cancer Research Network. Ethnicity and Disease, 12, 135-140.
29. Ford, M. E., Havstad, S. L. and Tilley, B. C. (2003). Recruiting older African American men to a cancer screening trial (The AAMEN Project). The Gerontologist, 43, 27-35.
30. Fulton-Picot, S. J. F., Tierney, J., Mirpourian, N., Ericsson, J. M., Wright, J. T. Jr. and Powel, L. L. (2002). Engaging black older adults and caregivers in urban communities in health research. Journal of Gerontological Nursing, 28, 19-27.
31. Ganz, P. A. (1990). Clinical trials: concerns of the patient and the public. Cancer, 65 (Suppl. 10), 2394S-2399S.
32. Gelfand, D. E., Parzuchowski, J., Cort, M. and Powell, I. (1995). Digital rectal examination and prostate cancer screening: attitudes of African American men. Oncology Nursing Forum, 22, 1253-1255.
33. Gohagan, J. K., Prorok, P. C., Hayes, R. B. and Kramer, B. S. (2000). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Controlled Clinical Trials, 21 (Suppl. 6), S251-S272.
34. Goodman, A. H. (2000). Why genes don't count (for racial differences in health). American Journal of Public Health, 90, 1699-1702.
35. Gurland, B. J. et al. (1999). Rates of dementia in three ethnoracial groups. Internal Journal of Geriatric Psychiatry, 14, 481-493.
36. Harrison, F. V. (1995). The persistent power of "race" in the cultural and political economy of racism. Annual Review of Anthropology, 24, 47-74.
37. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A. and Evans, D. A. (2003). Alzheimer disease in the US population: prevalence estimates using the 2000 census. Archives of Neurology, 60, 1119-1122.
38. Hendrie, H. C. (1998). Epidemiology of dementia and Alzheimer's disease. American Journal of Geriatric Psychiatry, 6, S3-S18.
39. Hendrie, H. C. et al. (1995). Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. The American Journal of Psychiatry, 152, 1485-1492.
40. Hendrie, H. C., Murrell, J., Gao, S., Unverzagt, F. W., Ogunniyi, A. and Hall, K. S. (2006) International studies in dementia with particular emphasis on populations of African origin. Alzheimer Disease and Associated Disorders, 20 (Suppl 2), S42-S46.
41. Hinton, L., Franz, C. E., Yeo, G. and Levkoff, S. E. (2005). Conceptions of dementia in a multiethnic sample of family caregivers. Journal of the American Geriatrics Society, 53, 1405-1410.
42. Holston, E. C. (2005). Stigmatization in Alzheimer's disease research on African American elders. Issues in Mental Health Nursing, 25, 1103-1127.
43. Hunninghake, D. B., Darby, C. A. and Probstfield, J. L. (1987). Recruitment experience in clinical trials: literature summary and annotated bibliography. Controlled Clinical Trials, 8 (Suppl.), S6-S30.
44. Hutchinson, J. (1992). AIDS and racism in America. Journal of the National Medical Association, 84, 119-124.
45. Jackson, J. S., Chatters, L. M. and Taylor, R. I. (1993). Aging in Black America. Newbury Park, California: Sage Publications.
46. Johansen, M. A., Mayer, D. K. and Hoover, H. C. Jr. (1991). Obstacles to implementing cancer clinical trials. Seminars in Oncology Nursing, 7, 260-267.
47. Kamoi, K. and Babaian, R. J. (1999). Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer. Seminars in Oncology, 26, 140-149.
48. Kaart, C. S. and Ford, M. E. (2002). Exploring the factorial structure of the EORTC QLQ-C30: racial differences in measuring health-related quality of life in a sample of urban, older adults. Journal of Aging and Health, 14, 399-421.
49. Kaufman, J. S., Cooper, R. S. and McGee, D. L. (1997). Socioeconomic status and health in blacks and whites: the problem of residual confounding and the resiliency of race. Epidemiology, 8, 621-628.
50. Kindig, D. A. and Yan, G. (1993). Physician supply in rural areas with large minority populations. Health Affairs, 12, 177-184.
51. Kubota, T., Yamaura, Y., Ohkawa, N., Hara, H. and Chiba, K. (2000). Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. British Journal of Clinical Pharmacology, 50, 31-34.
52. Lewontin, R., Rose, S. and Kamin, G. (1984). Not in our Genes: Biology, Ideology, and Human Nature. New York: Pantheon.
53. Liang, J., Lawrence, R. H. and Bollen, K. A. (1987). Race differences in factorial structures of two measures of subjective well-being. Journal of Gerontology, 42, 426-428.
54. Loewenstein, D. A, Arguelles, T., Arguelles, S. and Linn-Fuentes, P. (1994). Potential cultural bias in the neuropsychological assessment of the older adult. Journal of Clinical and Experimental Neuropsychology, 16, 632-639.
55. Manly, J. J. et al. (1998). Cognitive test performance among nondemented elderly African Americans and Whites. Neurology, 50, 1238-1245.
56. Manly, J. J., Jacobs, D. M. and Mayeux, R. (1999). Alzheimer disease among different ethnic and racial groups. In R. D. Terry, R. Katzman, K. L. Bick and S. S. Sisodia (eds.), Alzheimer Disease (pp. 117-132). Philadelphia, PA: Lippincott Williams & Wilkins.
57. Manly, J. et al. (2000). Are ethnic group differences in neuropsychological test performance explained by reading level? A preliminary analysis. Journal of the International Neuropsychology Society 6, 245.
58. Manly, J. J., Jacobs, D. M., Touradji, P., Small, S. A. and Stern, Y. (2002). Reading level attenuates differences in neuropsychological test performance between African American and White elders. Journal of the International Neuropsychological Society, 8, 341-348.
59. Manly, J. J., Touradji, P., Tang, M-X., and Stern, Y. (2003). Literacy and memory decline among ethnically diverse elders. Journal of Clinical and Experimental Neuropsychology, 25, 680-690.
60. Manly, J. J., Byrd, D., Touradji, P. and Stern, Y. (2004a). Acculturation, reading level, and neuropsychological test performance among African American elders. Applied Neuropsychology, 11, 37-46.
61. Manly, J. J., Byrd, D., Touradji, P., Sanchez, D. and Stern, Y. (2004b). Literacy and cognitive change among ethnically diverse elders. International Journal of Psychology, 39, 7-60.
62. Manly, J. J., Schupf, N., Tang, M-X. and Stern, Y. (2005). Cognitive decline and literacy among ethnically diverse elders. Journal of Geriatric Psychiatry and Neurology, 18, 213-217.
63. Marin, G. and Perez-Stable, E. J. (1995). Effectiveness of disseminating culturally appropriate smoking-cessation information: Programa Latino Para Dejar de Fumar. Journal of the National Cancer Institute. Monographs, 18, 155-163.
64. Marin, G. et al. (1995). A research agenda for health education among underserved populations. Health Education Quarterly, 22, 346-363.
65. McCabe, M. S., Varricchio, C. G. and Padberg, R. M. (1994). Efforts to recruit the economically disadvantaged to national clinical trials. Seminars in Oncology Nursing, 10, 123-129.
66. Millon-Underwood, S., Sanders, E. and Davis, M. (1993). Determinants of participation of state-of-the-art cancer prevention, early detection/screening, and treatment trials among African Americans. Cancer Nursing, 16, 25-33.
67. Mintzer, J., Faison, W., Aerssens, J., McRae, T., Moore, K. and Sano, M. (2001). First report on genetics, response, and cognitive enhancers in ethnically and racially diverse Alzheimer's disease patients (GRACE Conference). Poster presented at the American College of Neuropsychopharmacology, December.
68. Mouton, C. P. (1997). Special health considerations in African-American elders. American Family Physician, 55, 1243-1253.
69. National Institute of Mental Health (2006). Policy for the Recruitment of Participants in Clinical Research, at www.nimh.nih.gov/ researchfunding/nimhrecruitmentpolicy.cfm
70. Olin, J. T, Dagerman, K. S., Fox, L. S., Bowers, B. and Schneider, L. S. (2002). Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Disease and Associated Disorders, 16, S82-S99.
71. Ornstein, D. K. and Pruthi, R. S. (2000). Prostate-specific antigen. Expert Opinion on Pharmacotherapy, 1, 1399-1411.
72. Perkins, P., Annegers, J. F., Doody, R. S., Cooke, N., Aday, L. and Vernon, S. W. (1997). Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology, 49, 44-50.
73. Prorok, P. C. et al. (2000). Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 21(Suppl. 6), 273S-309S.
74. Rebbeck, T. R. (2002). Inherited genotype and prostate cancer outcomes. Cancer Epidemiology, Biomarkers & Prevention, 11, 945-952.
75. Risch, N., Burchard, E., Ziv, E. and Tang, H. (2002). Categorization of humans in biomedical research: genes, race, and disease. Genome Biology, 3, DOI:10.1186/gb-2002-3-7-comment2007.
76. Roberts, J. S., Connel, C. M., Cisewski, D., Hipps, Y. G., Demissie, S. and Green, R. C. (2003). Differences between African Americans and Whites in their perceptions of Alzheimer disease. Alzheimer Disease and Associated Disorders, 17, 19-26.
77. Royal, C. et al. (2000). Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Annals of Epidemiology, 10 (Suppl. 8), S68-S77.
78. Rubin, R. R. et al. (2002). The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials, 23, 157-171.
79. Schneider, L. (2005). Drug development, clinical trials, cultural heterogeneity in Alzheimer disease. Alzheimer Disease and Associated Disorders, 14, 279-283.
80. Schneider, L. S. et al. (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine, 355, 1525-1538.
81. Sano, M. et al. (1997). The Spanish Instrument Protocol: design and implementation of a study to evaluate treatment efficacy Instruments for Spanish-speaking patients with Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S57-S64.
82. Stallings, F. I. et al. (2002). Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 21 (Suppl. 6), 379S-389S.
83. Still, C. N., Jackson, K. L., Brandes, D. A., Abramson, R. K. and Macera, C. A. (1990). Distribution of major dementias by race and sex in South Carolina. Journal of the South Carolina Medical Association, 86, 453-456.
84. Swanson, G. M. and Ward, A. J. (1995). Recruiting minorities into clinical trials: toward a participant-friendly system. Journal of the National Cancer Institute, 87, 1747-1759.
85. Tang, M. S. et al. (2001). Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology, 56, 49-56.
86. Tangrea, J. A., Adrianza, M. E. and Helsel, W. E. (1992). Patients' perceptions on participation in a cancer chemoprevention trial. Cancer Epidemiology, Biomarkers & Prevention, 1, 325-330.
87. Tariot, P. N. et al. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291, 317-324.
88. Teresi, J. A., Golden, R. R., Cross, P., Gurland, B., Kleinman, M. and Wilder, D. (1995). Item bias in cognitive screening measures: comparisons of elderly white, Afro-American, Hispanic and high and low education subgroups. Journal of Clinical Epidemiology, 48, 473-483.
89. Thompson, E. E, Neighbors, H. W., Munday, C. and Jackson, J. S. (1996). Recruitment and retention of African American patients for clinical research: an exploration of response rates in an urban psychiatric hospital. Journal of Consulting and Clinical Psychology, 64, 861-867.
90. Valle, R. (1994). Culture-fair behavioral symptom differential assessment and intervention in dementing illness. Alzheimer Disease and Associated Disorders, 8 (Suppl. 3), 21-45.
91. Varsaldi, F. et al. (2006). Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. European Journal of Clinical Pharmacology, 62, 721-726.
92. Wilkinson, D. Y. and King, G. (1987). Conceptual and methodological issues in the use of race as a variable: policy implications. The Milbank Quarterly, 65 (Suppl 1), 56-71.
93. Woods, M. N., Harris, K. J., Mayo, M. S., Catley, D., Scheibmmmeir, M. and Ahluwalia, J. S. (2002). Participation of African Americans in a smoking cessation trial: a quantitative and qualitative study. Journal of the National Medical Association, 94, 609-618.
94. Xu, C. et al. (2002). An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochemical and Biophysical Research Communications, 290, 318-324.